Mineralys director exercises options, sells shares
Mineralys Therapeutics director Daphne Karydas reported an option exercise and share sale.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics director Daphne Karydas reported an option exercise and share sale. She exercised stock options to acquire 3,000 shares of common stock at $12.02 per share, then sold 3,000 common shares in an open-market transaction at $25.00 per share.
After these transactions, she directly holds 6,200 shares of common stock and 41,000 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,000 shares ($39K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Karydas Daphne
Role
Director
Sold
3,000 shs ($75K)
Approx. gross sale proceeds
$75K
Approx. exercise cost
$36K
Approx. pre-tax spread
$39K
Share of Position Sold
32.6%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 3,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,000 | $12.02 | $36K |
| Sale | Common Stock | 3,000 | $25.00 | $75K |
Holdings After Transaction:
Stock Option — 41,000 contracts (Direct);
Common Stock — 6,200 shares (Direct)
Holdings Before and After:
Stock Option, 44,000 to 41,000 contracts (Direct);
Common Stock, 6,200 to 6,200 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
- F2. The stock option vests in 36 monthly installments beginning on October 13, 2023.
Key Figures
Options exercised: 3,000 shares
Exercise price: $12.02/share
Shares sold: 3,000 shares
+5 more
8 metrics
Options exercised
3,000 shares
Stock options exercised into common stock at $12.02 per share
Exercise price
$12.02/share
Strike price for 3,000 exercised stock options
Shares sold
3,000 shares
Common stock sold in open-market transaction at $25.00
Sale price
$25.00/share
Price for 3,000 Mineralys Therapeutics common shares sold
Common shares held
6,200 shares
Direct Mineralys Therapeutics common stock ownership after transactions
Options held
41,000 options
Stock options outstanding after the reported exercise
10b5-1 plan adoption date
December 30, 2025
Pre-arranged trading plan governing the reported transactions
Option vesting term
36 monthly installments
Vesting schedule beginning October 13, 2023
Key Terms
Rule 10b5-1 trading plan, Stock Option, Exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option financial
"security_title": "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mineralys Therapeutics (MLYS) director Daphne Karydas report?
Daphne Karydas reported exercising stock options for 3,000 Mineralys Therapeutics shares, then selling 3,000 common shares in an open-market transaction. These moves converted option-based compensation into stock and then into cash while leaving her with a continuing equity position.
At what price did the Mineralys Therapeutics (MLYS) director exercise her stock options?
She exercised stock options covering 3,000 underlying Mineralys Therapeutics shares at an exercise price of $12.02 per share. This transaction converted derivative securities into common stock as part of her equity compensation arrangement with the company.
What are Daphne Karydas’s holdings in Mineralys Therapeutics (MLYS) after these transactions?
After the reported transactions, she directly holds 6,200 shares of Mineralys Therapeutics common stock and 41,000 stock options. These positions show she retains both current share ownership and a significant remaining option-based interest in the company.
Were the Mineralys Therapeutics (MLYS) insider trades made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Such plans pre-schedule trades, which can make the timing less indicative of the insider’s short-term market view.
How do the Mineralys Therapeutics (MLYS) option terms affect the director’s compensation?
The filing notes that the stock option vests in 36 monthly installments beginning October 13, 2023. This structure gradually delivers exercisable options over three years, aligning a portion of the director’s compensation with Mineralys Therapeutics’ long-term share performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
